Medpace Holdings, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Medpace is a global, single-segment contract research organization providing full-service Phase I–IV clinical development and laboratory services to biotechnology, pharmaceutical, and medical-device companies. It had approximately 5,200 employees across 40 countries at year-end. Small and mid-sized biopharmaceutical companies accounted for 78% and 16% of FY2022 revenue, respectively.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $1,460.0 million | $1,142.4 million | +27.8% |
| Income from operations | $278.7 million | $198.6 million | +40.3% |
| Operating margin | 19.1% | 17.4% | +1.7 percentage points |
| Net income | $245.4 million | $181.8 million | +34.9% |
| Net margin | 16.8% | 15.9% | +0.9 percentage points |
| Diluted EPS | $7.28 | $4.81 | +51.4% |
| Cash from operations | $388.1 million | $263.3 million | +$124.7 million |
Revenue growth was broad-based, led by Oncology, Metabolic, Cardiology, and Central Nervous System. Total direct costs rose 26.2%, slower than revenue growth; SG&A increased 21.2%. The effective tax rate rose to 13.3% from 9.9%.
Capital expenditures were $36.9 million, implying operating cash flow less capital expenditures of approximately $351.2 million. Cash and cash equivalents fell to $28.3 million from $461.3 million, primarily reflecting share repurchases. Year-end debt was $50.0 million; reported available borrowing under the $250 million revolving facility was $199.8 million. The facility bore interest at 5.3% at year-end and was due to expire March 31, 2023; management expected to amend it or obtain a replacement before then. Current assets were $334.0 million and current liabilities $803.5 million; current liabilities include substantial customer advance billings.
Backlog, outlook, and material changes
- Net new business awards increased to $1,829.5 million from $1,610.4 million.
- Backlog rose 17.2% to $2,339.6 million at year-end. Management expected approximately $1.20–$1.22 billion to convert to revenue in 2023; backlog conversion is subject to cancellations, delays, scope changes, and other uncertainties.
- FY2022 financing cash outflow was $775.8 million, including $847.8 million of share repurchases, partly offset by net $50.0 million of revolving-credit borrowings. A new $500 million repurchase authorization was approved in Q4; $452.8 million remained at year-end.
- No formal earnings or revenue guidance is stated in the supplied filing text. Management said liquidity was expected to cover needs for the next 12 months and longer term, while cautioning that future operating cash flow and borrowing availability are not assured.
Risks, contingencies, and unusual items
- Most contracts are terminable by customers, generally on 30 days’ notice. Backlog is not a guaranteed revenue measure, and delayed or cancelled trials can affect utilization and margins.
- Fixed-fee contracts expose Medpace to underpricing, cost overruns, and delays in obtaining documented change orders. Revenue estimates rely on forecasts of total contract costs; revenue recognition was identified as the auditor’s critical audit matter.
- Customer and funding concentration are relevant: the top ten customers represented about one-fourth of revenue, and smaller biotechnology customers may have limited access to capital.
- Inflation in labor, materials, and transportation costs may not be fully offset by pricing and productivity measures. Foreign exchange movements also affect results; a 10% adverse rate movement was estimated to reduce FY2022 pretax income by about $13.0 million.
- COVID-19 effects, clinical-trial enrollment and site constraints, cybersecurity and privacy, regulatory compliance, third-party service dependence, and competition remain identified risks.
- Government assistance income, net, was $15.4 million in FY2022 and reduced SG&A. Related-party transactions include customer work, leases, and travel services involving entities connected to executives, including the CEO.
- Management reported no pending legal matter expected to have a material adverse financial effect. Deloitte issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Whether the $1.20–$1.22 billion of expected 2023 backlog conversion is achieved, and how cancellations and project timing affect revenue.
- Credit-facility renewal or replacement terms, borrowing capacity, interest costs, and liquidity after substantial buybacks.
- Whether revenue and margin growth can continue as staffing costs, inflation, and trial-delivery costs change.
- How customer funding conditions and the high share of revenue from small and mid-sized biopharma companies affect awards, collections, and cancellations.
- The sustainability and terms of share repurchases, and the financial and governance implications of related-party transactions and the CEO’s voting influence.